Improves HFD-induced Hepatic Steatosis by Upregulating Hepatic STAMP2 Expression Through AMPK

Yoo Jin Oh, Hye Young Kim, Mi Hwa Lee, Sung Hwan Suh, Yongmun Choi, Tae-gyu Nam, Woo Young Kwon, Sang Yeob Lee and Young Hyun Yoo*

Department of Anatomy and Cell Biology, Dong-A University College of Medicine, Busan, Republic of Korea (Y.J.O., H.Y.K., M.H.L., W.Y.K., Y.H.Y.); Department of Endocrinology Medicine, Dong-A University College of Medicine, Busan, Republic of Korea (S.H.S.); Gyeonggi Bio Center, Gyeonggi-do Business and Science Accelerator, Suwon, Republic of Korea (Y.C.); Department of Pharmacy and Institute of Pharmaceutical Science and Technology, Hanyang University, Ansan, Republic of Korea (T.-G.N.); Department of Rheumatology, Dong-A University College of Medicine, Busan, Republic of Korea (S.Y.L.)

Y.J.O. and H.Y.K. contributed equally to this work.

Keywords: NAFLD; Hepatic steatosis; Cilostazol; STAMP2; AMPK.
Running Title

Cilostazol-mediated Amelioration of Hepatic Steatosis

To whom correspondence should be addressed: Young Hyun Yoo, M.D. Department of Anatomy and Cell Biology, Dong-A University College of Medicine, 32, Daesingongwon-ro, Seo-Gu, Busan 602-714, Republic of Korea, Telephone: +82 51 240 2637; FAX: +82 51 241 3767; E-mail: yhyoo@dau.ac.kr

Text pages: 39
Figures: 7
References: 43
Abstract Word Count: 223
Introduction Word Count: 476
Discussion Word Count: 1039

Abbreviations: AMP-activated protein kinase, AMPK; free fatty acids, FFA; high-density lipoprotein-cholesterol, HDL-C; high-fat diet, HFD; intraperitoneal glucose tolerance test, IPGTT; liver X receptor α, LXRα; non-alcoholic fatty liver disease, NAFLD; non-alcoholic steatohepatitis, NASH; non-esterified fatty acids, NEFA; oleic acid, OA; standard diet, SD; sterol regulatory element-binding protein-1c, SREBP-1c; six transmembrane protein of prostate 2, STAMP2; six transmembrane epithelial antigen of prostate 4, STEAP4; total cholesterol, TC; TNF-induced adipose related protein, TIARP
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is an increasingly studied condition that may progress to end-stage liver disease. Although NAFLD was first described in 1980, a complete understanding of the mechanism and causes of this disease is still lacking. Six transmembrane protein of prostate 2 (STAMP2) plays a role in integrating inflammatory and nutritional signals with metabolism. Our previous study suggested that STAMP2 may be a suitable target for treating NAFLD. In the current study, we, performing a focused drug screening, found that cilostazol could be a potential STAMP2 enhancer. Thus, we examined whether cilostazol alleviates NAFLD through STAMP2. The in vivo and in vitro pharmacological efficacies of cilostazol on STAMP2 expression and lipid accumulation were analyzed in NAFLD mice induced by high fat diet (HFD) and HepG2 cell lines treated by oleic acid (OA), respectively. Cilostazol increased the expression of STAMP2 through transcriptional regulation in vivo and in vitro. Cilostazol also dampened the STAMP2 downregulation caused by the HFD and by oleic acid (OA) in vivo and in vitro, respectively. Cilostazol activated AMPK (AMP-activated protein kinase) in vivo and in vitro, and AMPK functions upstream of STAMP2, and reverted downregulation of STAMP2 expression through AMPK in NAFLD model. Cilostazol ameliorates hepatic steatosis by enhancing hepatic STAMP2 expression through AMPK. Enhancing STAMP2 expression with cilostazol represents a potential therapeutic avenue for treatment of NAFLD.
Introduction

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases in the world. NAFLD is characterized by fatty liver, due to excessive lipid accumulation in the liver. NAFLD has been known as the hepatic manifestation of metabolic syndromes including insulin resistance (Marchesini et al., 2003; Cohen et al., 2011; Day and James, 1998; Anstee and Goldin, 2006).

Six transmembrane protein of prostate 2 (STAMP2), which is also known as TNF-induced adipose related protein (TIARP) or six transmembrane epithelial antigen of prostate 4 (STEAP4), belongs to a family of six transmembrane proteins called either the STAMP or STEAP family (Korkmaz et al., 2005). Although the STAMP2 protein was first identified as a prostate-specific antigen (Hubert et al., 1999), STAMP2 has been reported to play a role in coordinating the regulation of nutrient and inflammatory responses in adipose tissue (Wellen et al., 2007; Arner et al., 2008).

STAMP2 is known to be abundantly expressed in adipose tissue, and STAMP2 expression is elevated in fed mice compared to that in fasting mice. Previous studies have shown that nutritional regulation of STAMP2 expression in adipose tissue is lost in ob/ob and diet-induced obesity models. In vitro gain-of-function studies showed that STAMP2 increases insulin sensitivity. In contrast, in vitro and in vivo the loss of STAMP2 function
studies showed that STAMP2 deficiency elevates inflammatory markers, diminishes insulin action and sensitivity, and hinders glucose uptake (Wellen et al., 2007; Waki and Tontonoz, 2007; Abedini and Shoelson, 2007).

Based on these previous findings, STAMP2 may play a role in integrating inflammatory and nutritional signals with metabolism (Yoo et al., 2014). Previous studies demonstrated that STAMP2 is expressed in the liver (Korkmaz et al., 2005; Ramadoss et al., 2010). A report demonstrating that there is notable fat accumulation and severe impairment of insulin receptor signaling in the livers of STAMP2-/- mice indicates that hepatic STAMP2 has a role in regulating lipid and insulin homeostasis (Wellen et al., 2007). CCAAT/enhancer-binding protein β (C/EBP β) was shown to directly regulate the roles of STAMP2 and its novel variant in attenuating lipogenesis, gluconeogenesis and/or inflammation elicited by free fatty acids (FFAs) or lipopolysaccharide (LPS) in hepatocytes (Wang et al., 2013). A study on the hepatic role of STAMP2 demonstrated the involvement of hepatic STAMP2 in HBx protein-associated metabolic dysregulation (Kim et al., 2012). Our previous study illustrated that hepatic STAMP2 plays a pivotal role in preventing and improving high-fat diet (HFD)-induced hepatic steatosis and insulin resistance in NAFLD (Kim et al., 2015).

In this study, we first performed a high-throughput screening to identify a STAMP2 enhancer and found that cilostazol could be a potential candidate. Thus, we examined whether cilostazol ameliorates lipid accumulation in oleic acid (OA)-treated HepG2 cells and HFD-induced fatty liver NAFLD model
through STAMP2. We observed that cilostazol improves HFD-induced hepatic steatosis by modulating STAMP2 expression through AMPK (AMP-activated protein kinase).
Materials and Methods

High-throughput screening. A pilot-scale screening was conducted at the Gyeonggi Bio Center (Suwon, Gyeonggi-do, Korea). Hela cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 10% FBS, 1% penicillin and streptomycin at 37 °C, and 5% CO₂-95% air. For screening, cells were seeded into 60 mm dished and in cultured DMEM/10% FBS without 1% P/S. FuGENE HD transfection reagent (Roche Diagnostics, Indianapolis) was used for high-throughput transfections at 1 µl of FuGENE HD 3 per µg of total DNA. After 16 h incubation at 37 °C, 4 µl of the mix from each well was transferred to a 384-well tissue culture plate and incubated for 18 h. Luciferase using the Bright-Glo™ Luciferase Assay (Promega) and Luminescence signal was measured with an automated plate reader (Perkin-Elmer Envision 1). Small molecule libraries consisting of 2,000 diverse compounds were used in the screen. The compounds were selected from the DIVERSet library, the Kinase-directed library, the PremiumSet library, and the GPCR library (ChemBridge, San Diego), and Hela cells were treated with compounds at a 20 µM final concentration for 24 h. Oleic acid (500 µM) and DMSO were used as positive and negative controls, respectively. Primary screening identified 50 compounds with a cutoff level of a 2-fold signal change relative to the DMSO control. To validate the 50 primary hits, confirmation screens in which each compound
was tested with multiple replicates was conducted to identify 18 compounds that showed reproducible fold changes.

**Materials.** Cilostazol, OA, free bovine serum albumin (BSA), AICAR, Compound C, Oil Red O and the antibodies against β-actin were purchased from Sigma-Aldrich (St. Louis, MO, USA). The antibodies against sterol regulatory element-binding protein-1c (SREBP-1c) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), the antibodies against liver X receptor α (LXRα) were obtained from Abcam (Cambridge, MA, USA) and STAMP2 were obtained from Proteintech (Chicago, IL, USA). The antibodies against AMPKα, p-AMPKα (Thr172), HRP-conjugated goat anti-rabbit and horse anti-mouse IgG were purchased from Cell Signaling (Danvers, MA, USA).

**Animals and treatments.** Male C57BL/6 mice (22-25g, Samtako, Inc. Osan, South Korea) were maintained on a 12 h light–dark cycle with free access to water and food. Five-week-old mice were fed a standard diet (SD) or a HFD for 15 weeks and then randomly divided into four groups. The mice in the SD group were fed a SD and orally administered vehicle (DMSO) (SD+Veh group, n=9) or cilostazol (30 mg/kg/d) (SD+Cilo group, n=9), whereas dyslipidemic mice were fed a HFD (HFD group, 60 % fat) (Feed Lab. Guri, South Korea) and received either orally administered vehicle (HFD+Veh...
group, n=27) or cilostazol (HFD+Cilo group, n=21). After 3, 6 and 9 weeks of treatment, the mice were anesthetized with avertin (Sigma-Aldrich) and sacrificed for tissue sampling after 8 h of starvation. Blood was collected by cardiac puncture and stored at −20 °C in autoclaved E-tubes. Livers were isolated, immediately fixed in 10 % neutral-buffered formalin (NBF) solution, and stored at 4 °C until assays were performed. All procedures were approved by the Committee on Animal Investigations at Dong-A University (DIACUC-15-12).

**Cell culture and treatment.** HepG2 cells were obtained from the American Type Culture Collection (Manassas, VA, USA). The cells were cultured in DMEM (Gibco, Grand Island, NY, USA) containing 10 % FBS and 1 % (v/v) penicillin-streptomycin. The cells were maintained in subconfluent conditions in a humid atmosphere of 95 % air and 5 % CO₂ at 37 °C. Fatty acids were conjugated with 0.1 % free fatty acids (FFAs)-free BSA in DMEM. OA was added to the serum-containing cell culture medium to achieve a fatty acid concentration of 500 μM. HepG2 cells were treated with 500 μM OA and cilostazol for 24 h.

**Histology staining.** For histopathological analyses, portions of liver were fixed (10 % NBF), dehydrated, and embedded in paraffin. Four- micrometer
thick sections were mounted on glass slides, deparaffinized in xylene, rehydrated in graded ethanol, and stained with hematoxylin and eosin. The morphology of the liver tissue was photographed using a Pannoramic MIDI-II Digital Scanner (3D Histech, Budapest, HUNGARY).

**Immunohistochemical staining.** Immunohistochemistry was performed on four-micrometer thick liver sections. The sections were incubated with primary rabbit polyclonal STAMP2 antibody at 4 °C overnight and then with a matching biotinylated secondary antibody for 60 min at 37 °C, then slides were incubated in DAB and hydrogen peroxide substrate. The negative controls did not have the primary antibody. The sections were developed with diaminobenzidine, counterstained with hematoxylin. The results were viewed using a Pannoramic MIDI-II Digital Scanner.

**Oil Red O staining.** Confluent HepG2 cells were exposed to DMEM (0.1 % BSA) in the presence or absence of cilostazol with OA. After 24 h, cells were washed in PBS and fixed using 4 % (w/v) para-formaldehyde for 60 min at room temperature. After three washes in 60 % isopropanol, the cells were stained with freshly diluted Oil Red O solution for 20 min. Then, the stain was removed, and the cells were washed four times in distilled water. To quantify intracellular lipid accumulation, Oil Red O solution was extracted using 100 % isopropanol and the absorbance was measured at 500nm using a
spectrophotometer.

**Plasma glucose concentrations and tolerance tests for glucose.** Intraperitoneal glucose tolerance tests (IPGTT) was performed after the mice were fasted for 16 h. Plasma glucose concentrations were measured in tail blood using a Gluco-Dr Blood Glucose Test Strip (Hasuco, Seoul, South Korea) prior to and 30, 60, 90, and 120 min after intraperitoneally injecting a bolus of glucose (1 mg/g) for the IPGTT.

**Analysis of plasma TC levels, NEFA levels and Insulin levels.** Plasma total cholesterol (TC), and non-esterified fatty acids (NEFA) were measured with an enzymatic, colorimetric test kit (Asan Pharmaceutical Co., Seoul, Korea). Plasma insulin was detected using a mouse insulin ELISA kit (Shibayagi, Gunma, Japan).

**Luciferase assay.** HepG2 cells were plated in a 24-well culture plate and transfected with a reporter vector (0.2 μg) together with each indicated expression plasmid using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA), according to the manufacturer’s instructions. The luciferase activities were measured using the Dual Luciferase Reporter Assay System (Promega, Madison, WI, USA), according to the manufacturer’s instructions. Firefly luciferase activities were standardized to Renilla activities.
RNA isolation and RT-PCR. Total RNA was prepared from cell lines or tissues using TRIzol reagent (Invitrogen), according to the manufacturer's instructions. The cDNA was synthesized from 3 μg of total RNA with MMLV reverse transcriptase (Promega) using a random hexamer (Cosmo, Korea) at 42 °C for 60 min. The PCR primers for human STAMP2 gene amplification were: 5’-CGA AAC TTC CCT CTA CCC G-3’ (sense), 5’-ACA CAA ACA CCT GCC GAC TT-3’ (antisense); for human β-actin gene amplification: 5’-GAC TAC CTC ATG AAG ATC-3’ (sense), 5’-GAT CCA CAT CTG CTG GAA-3’ (antisense). The cDNAs were amplified by PCR under the following conditions: 30 cycles of denaturation at 95 °C for 20 s, annealing at 56 °C for 30 s, and extension at 72 °C for 30 s in a thermal cycler.

Real-time PCR. A one-tenth aliquot of cDNA was subjected to PCR amplification using mouse gene-specific primers: mouse Stamp2, 5’-GGT TGT CTG CAT TTT CGG AAC-3’ (sense), 5’-GGT TTC GAC TCC CAA AAA CGA-3’ (antisense); mouse Gapdh, 5’-AGG TCG GTG TGA ACG GAT TTG-3’ (sense), 5’-GGG GTC GTT GAT GGC AAC A-3’ (antisense). Real-time PCR was performed using SYBR Green PCR Master Mix (Applied Biosystems, Foster City, CA) with an ABI 7500 instrument (Applied Biosystems).

Western blot analysis. Cells were washed with PBS, resuspended in ice-
cold lysis buffer and incubated at 4 °C for 20 min. Lysates were centrifuged at 13,000 rpm for 20 min at 4 °C. Twenty μg of proteins was loaded onto 7.5–15 % sodium dodecyl sulfate polyacrylamide gel electrophoresis. The proteins were transferred onto nitrocellulose membrane (Amersham Pharmacia Biotech, Piscataway, NJ, USA) and reacted with each antibody. Western blot analysis with antibodies was performed with Super Signal West Pico (Thermo Scientific, Hudson, NH, USA; Waltham, MA, USA) enhanced chemiluminescence substrate and detected using the LAS-3000 Plus (Fuji Photo Film, Tokyo, Japan). Quantification and normalization to actin control bands using Image J version 1.48q.

**Nile Red staining.** Cells were fixed with 4 % paraformaldehyde for 60 min and stained with Nile Red (1 μg/ml) in the dark for 10 min at room temperature. The red and green fluorescence signals in the cells were imaged using a Zeiss LSM 800 laser-scanning confocal microscope (Göttingen, Germany).

**RNA interference and transfection.** For the siRNA-mediated downregulation of STAMP2, siRNAs targeting STAMP2 and negative control scRNA were purchased from Sigma (St. Louis, MO, USA). HepG2 cells were transfected with either siRNA specific for STAMP2 or a negative control scRNA using Lipofectamine RNAi MAX (Invitrogen) according to
the manufacturer's instructions.

**Adenoviral STAMP2 infection.** Recombinant adenoviral STAMP2 (Ad-STAMP2) was prepared as described previously (Kim et al., 2015). HepG2 cells were infected with recombinant Ad-STAMP2 at multiplicity of infection (MOIs) of 100.

**Statistical analysis.** The results are expressed as the means ± S.D. from three experiments. Statistical significance between two groups was determined by unpaired two-tailed Student’s t test. For comparison among multiple groups, at least three independent experiments in triplicate were conducted. Shapiro-Wilk test was conducted to check normality of data and Levene's test verified homogeneity of variances before one-way analysis of variance (ANOVA). ANOVA followed by Scheffe's test was used for the analysis of differences within each treated conditions. \( p < 0.05 \) indicated statistical significance.
Results

High-throughput screening. A pilot-scale screening was conducted at the Gyeonggi Bio Center (Suwon, South Korea). Renilla luciferase activity driven by STAMP2 expression was measured. Primary screening found 41 upregulating compounds and 9 downregulating compounds with 2-fold or greater signal changes in the STAMP2 expression level relative to the DMSO control. To test the reproducibility and specificity of the 50 primary hits, we conducted a confirmation screening in which each compound was tested with multiple replicates. As a result, 18 compounds were validated as STAMP2 modulators: 13 up-regulators (Fig. 1) and 5 down-regulators. Among the 13 up-regulators identified through the confirmation screening and additional assays, potential Michael acceptors (conjugated nitriles), metal chelators (hydroxyquinolines) and intercalators (polycyclic aromatics) were excluded to focus on a few chemical scaffolds of interest. Of these scaffolds, the 3,4-dihydroquinolin-2-one scaffold was commonly encountered in three hits. This scaffold is interesting and promising because it features a simple and flexible platform for derivatization from a drug discovery point of view. All three compounds containing 3,4-dihydroquinolin-2-one show acceptable cLogP values ranging from 3.24 - 3.96.

Cilostazol increases hepatic STAMP2 expression \textit{in vivo} and \textit{in vitro}. We
wanted to use more drug-like derivatives for further characterization. Thus, we performed an extensive structure search. We finally found that among marketed drugs, cilostazol has the same chemical scaffold. Because cilostazol has been widely used without significant complications in the clinical field, we chose this drug for further study. Immunohistochemical analysis (Fig. 2A), real time PCR (Fig. 2B) and Western blot assay (Fig. 2C) demonstrated that cilostazol (30mg/kg/d) increased the expression of STAMP2 in the liver of C57BL/6 mice. Relative luciferase assay showed that cilostazol enhances the promoter activity of STAMP2 in HepG2 cells in dose- and time-dependent manners (Fig. 2, D and E). RT-PCR and Western blot analysis showed that cilostazol at 10~100 μM enhances the expression of STAMP2 mRNA and protein in HepG2 cells, respectively (Fig. 2, F and G). The concentrations used for in vitro and in vivo studies are compared to clinical levels (Ota et al., 2008).

**Cilostazol attenuates HFD-induced NAFLD in mice.** To investigate the effects of cilostazol in NAFLD mice, male C57BL/6 mice were randomly divided into four groups: (1) SD+Veh; (2) SD+Cilo; (3) HFD+Veh; and (4) HFD+Cilo (Fig. 3A). We next examined whether cilostazol modulates insulin sensitivity and glucose metabolism in HFD-induced NAFLD mice. Cilostazol treatment for 9 weeks reversed the increase in blood glucose levels and plasma insulin levels induced by the HFD. Furthermore, cilostazol treatment significantly lowered blood glucose levels in glucose tolerance test (Fig. 3B).
Observation of the bodies and the livers of the mice showed that cilostazol treatment attenuated HFD-induced accumulation of lipids in the liver and the abdominal viscera. Cilostazol treatment for 9 weeks significantly reversed the HFD-induced increase in the ratio of liver to body weight (Fig. 3C). Liver histology by Hematoxylin and eosin staining showed that cilostazol treatment for 9 weeks markedly attenuated HFD-induced aberrant lipid accumulation (Fig. 3C). While plasma TC and NEFA levels were increased in mice fed a HFD compared to those in mice fed a SD, cilostazol treatment for 9 weeks reversed the increase in plasma TC and NEFA levels induced by the HFD (Fig. 3D). These phenotypes were not observed at 3 and 6 weeks following cilostazol treatment (data not shown). HFD-induced increase of the expression level of SREBP-1c and LXRα which are key lipogenic factors was significantly reversed by cilostazol treatment (Fig. 3E). These in vivo and in vitro assays indicate that cilostazol improves hepatic steatosis and insulin resistance in HFD-induced NAFLD in mice.

Cilostazol ameliorates lipid accumulation through hepatic STAMP2. Immunohistochemical analysis and Western blot analysis demonstrated that the expression of hepatic STAMP2 was markedly reduced in liver tissue obtained from the mice fed a HFD compared to that in mice fed a SD. Importantly, cilostazol reversed the reduced expression of hepatic STAMP2 in mice fed a HFD (Fig. 4A). High levels of plasma FFAs are implicated in the pathogenesis of NAFLD, because FFAs can accumulate in hepatocytes to
form lipid droplets. This condition was mimicked \textit{in vitro} by treating HepG2 cells with 500 \(\mu\)M OA. The HepG2 cells were incubated with 500 \(\mu\)M OA with or without cilostazol for 24 h. Oil Red O staining was performed to demonstrate whether cilostazol influenced lipid accumulation in the HepG2 cells treated with OA. Lipid accumulation was increased in the HepG2 cells incubated with 500 \(\mu\)M OA alone. Noticeably, cilostazol significantly reversed the OA-induced lipid accumulation (Fig. 4B). Western blot analysis showed that the expression levels of SREBP-1c and LXR\(\alpha\) proteins were increased by OA treatment, which was significantly reversed by cilostazol treatment in HepG2 cells (Fig. 4B). Cilostazol also reversed the reduction in STAMP2 expression caused by OA, as shown by the relative luciferase assays and Western blot analysis (Fig. 4C). To prove that cilostazol ameliorates lipid accumulation through STAMP2, we performed a STAMP2 knockdown assay \textit{in vitro}. An Western blot analysis showed that STAMP2 was efficiently depleted by silencing of STAMP2 (Fig. 4D). Notably, siSTAMP2 prevented the amelioration of OA-induced lipid accumulation caused by cilostazol (Fig. 4E). We examined whether siSTAMP2 modulates the effect of cilostazol on the expression of SREBP-1c and LXR\(\alpha\). siSTAMP2 reversed the attenuation of their expression by cilostazol (Fig. 4E). These findings suggest that improvement of hepatic steatosis by cilostazol may be associated with the restoration of STAMP2 expression.
AMPK is involved in the amelioration of lipid accumulation by cilostazol. AMPK plays a pivotal role in the functional network of hepatic steatosis (Kohjima et al., 2008). Thus, we next examined whether cilostazol ameliorates lipid accumulation through AMPK. We observed that a HFD significantly reduced the expression level of p-AMPKα compared to that in the experimental control (SD group). We further observed that cilostazol increased the expression level of p-AMPKα not only in mice fed a SD but also in mice fed a HFD (Fig. 5A). Additionally, cilostazol increased the expression level of p-AMPKα in OA-induced HepG2 cells (Fig. 5B). To prove that the efficacy of cilostazol is mediated through AMPK, we examined the effects of an AMPK activator AICAR or an AMPK inhibitor Compound C on cilostazol treatment. Whereas the cilostazol-induced attenuation of lipid accumulation and the expression level of SREBP-1c and LXRα proteins was reversed by Compound C but was augmented by AICAR (Fig. 5, C and D). These data indicate that AMPK involves in the amelioration of lipid accumulation by cilostazol.

AMPK functions upstream of STAMP2. We next examined whether AMPK activation modulates hepatic STAMP2 expression. Relative luciferase assay (Fig. 6A) and Western blot analysis (Fig. 6B) showed that the expression of hepatic STAMP2 was significantly increased by AICAR, but was decreased by Compound C (Fig. 6, A and B). Relative luciferase assay
showed that AICAR and Compound C significantly reversed oleic acid-induced down-regulation and cilostazol-induced up-regulation of STAMP2, respectively (Fig. 6C). Western blot assay also showed that the ability of cilostazol to reverse the OA-induced decrease in STAMP2 expression was inhibited by Compound C but was augmented by AICAR (Fig. 6D). We observed that siSTAMP2 had no effect on the AICAR-induced increase of p-AMPKα (Fig. 6E). We further observed that cilostazol increased p-AMPKα levels regardless of STAMP2 knockdown in OA-treated HepG2 cells (Fig. 6F). Noticeably, siSTAMP2 reversed the amelioration of OA-induced lipid accumulation by AICAR (Fig. 6G). We observed that Ad-STAMP2 had no effect on the AICAR-induced increase of p-AMPKα (Fig. 6H). We further observed that cilostazol increased p-AMPKα levels regardless of STAMP2 overexpression in OA-treated HepG2 cells (Fig. 6I). Noticeably, Ad-STAMP2 reversed the augmentation of OA-induced lipid accumulation by Compound C (Fig. 6J). These data, in conjunction with Fig. 5B, shows that AMPK functions upstream of STAMP2 for the amelioration of lipid accumulation by cilostazol.
NAFLD is a spectrum disorders ranging from isolated hepatic steatosis to NASH, which is the more aggressive form of fatty liver disease that may progress to cirrhosis and cirrhosis-related complications, including hepatocellular carcinoma (Bugianesi et al., 2002). NAFLD is strongly associated with the risk of more severe conditions such as cardiovascular disease and atherosclerosis (Targher 2007). Overweight, insulin resistance, a sedentary life-style and an altered dietary pattern as well as genetic factors and disturbances in intestinal barrier function are key risk factors for NAFLD. Despite intensive studies on the pathogenesis of NAFLD, knowledge about disease initiation and detailed molecular mechanisms involved in the progression of this disease is not entirely understood (Kanuri and Bergheim, 2013).

The primary treatment for NAFLD is weight reduction. However, because it is hard to maintain weight loss, a number of pharmacotherapy has been considered for NAFLD patients. New classes of medications have been developed on the base of the understanding of disease pathogenesis in recent years and drug repurposing strategy identified several currently available agents for NAFLD patients (Rotman and Sanyal, 2017). Some new agents that activate or inhibit nuclear receptor signaling, such as peroxisome proliferator-activated receptor β/δ (PPARβ/δ), PPARγ, farnesoid X receptor...
(FXR), and LXR, have shown clinical evidence of therapeutic benefit (Tanaka et al., 2017). However, most drugs under evaluation have not resulted in the solution of the complex nature of NAFLD (Wong et al., 2016), and no existing agent has been specifically approved for treating NAFLD and NASH (Cusi, 2016). Thus, development or identification of agents for treating this disease is an urgent challenging task.

STAMP2 plays a role in integrating inflammatory and nutritional signals with metabolism. An elaborate study demonstrated that STAMP2 expression is responsive to both nutritional and inflammatory signals. The study further showed that STAMP2 deficiency induces the accumulation of extra body fat and systemic insulin resistance. (Wellen et al., 2007). STAMP2 plays a critical function in metabolic and inflammatory pathways by acting in adipocytes and macrophages, which are required for normal metabolic homeostasis (ten Freyhaus et al., 2012). Our previous study revealed that deficiency of hepatic STAMP2 significantly accelerates hepatic steatosis and insulin resistance in HFD-induced NAFLD mice, indicating that STAMP2 may represent a suitable target for interventions targeting NAFLD (Kim et al., 2015).

Cilostazol is an antiplatelet drug that inhibits both primary and secondary platelet aggregation in response to adenosine diphosphate (ADP), collagen, epinephrine, and arachidonic acid (Kimura et al., 1985). The antiplatelet and vasodilator properties of cilostazol are attributed to its ability to elevate
intracellular levels of cyclic AMP (cAMP) via inhibition of cAMP phosphodiesterase (Okuda et al., 1993). Cilostazol is now being used for the treatment of intermittent claudication (Beebe et al., 1999). Furthermore, several more recent meta-analyses elucidated that cilostazol, compared to aspirin, not only had similar or even slightly better therapeutic effects in stroke prevention but also caused a significant reduction in hemorrhagic stroke (DiNicolantonio et al., 2013). Previous studies have reported that cilostazol contributes to the amelioration of dyslipidemia (Elam et al., 1998). In addition, early studies performed in Japan and the United States demonstrated a beneficial effect of cilostazol on lipoprotein metabolism characterized by an increase in high-density lipoprotein-cholesterol (HDL-C) and a reduction of plasma triglyceride (TG) levels (Ikewaki et al., 2002; Tani et al., 2000; Elam et al., 1998). Cilostazol seems to increase HDL-C levels, which contributes to the amelioration of dyslipidemia. However, the mechanism underlying the pharmacological efficacy of cilostazol has not been fully elucidated in the liver.

Previous studies have shown that cilostazol has beneficial effects on glucose metabolism both in vitro and in vivo (Kim et al., 2014; Park et al., 2009; Park et al., 2008). Adipose tissue remodeling and inflammation are key metabolic events associated with obesity-related insulin resistance (Osborn and Olefsky, 2012). Cilostazol attenuates TNFα-induced chronic inflammation in adipose tissue through suppressing TNFα production from macrophages, which leads to ameliorate systemic insulin resistance in obese diabetic mice (Wada et al., 2012).
Previous several reports have shown that cilostazol ameliorates lipid imbalances in NAFLD. Cilostazol appeared to exert beneficial effects against NAFLD (Fujita et al., 2008). Recently, Jung et al. demonstrated that cilostazol inhibits insulin-induced hepatic SREBP-1c expression via the inhibition of LXR and Sp1 activity, and suggested that cilostazol negatively regulates hepatic lipogenesis through the inhibition of SREBP-1c transcription (Jung et al., 2014). Another study showed that cilostazol ameliorated hepatic steatosis and increased ATP-binding cassette transporter A1 (ABCA1) expression in the hepatocytes (Jeon et al., 2015). However, the precise mechanism underlying the amelioration by cilostazol of lipid imbalance in NAFLD has not been clarified. We, in the present study, demonstrated that cilostazol improves lipid accumulation in NAFLD models through STAMP2. We observed that cilostazol treatment augments hepatic STAMP2 expression, which leads to hepatic steatosis amelioration. In addition, we observed that hepatic STAMP2 silencing prevents cilostazol from reducing lipid accumulation in HepG2 cells. AMPK phosphorylates key metabolic enzymes and transcriptional regulators such as fatty acid synthase, SREBP1, SREBP2, and acetyl-CoA Carboxylase (ACC) that are linked to controlling lipid biosynthesis (Day et al., 2017). Previous studies have shown that cilostazol activates AMPK in vascular smooth muscle and endothelial cells (Aoki et al., 2010; Suzuki et al., 2008). In the present study, we demonstrated that cilostazol activates AMPK
and ameliorates lipid imbalances in NAFLD. In addition, we demonstrated that cilostazol increases the expression of hepatic STAMP2 through AMPK (Fig. 7). Irrespective of our data, our study lacks in vivo loss-of-function assessment. We previously demonstrated that liver specific deletion of STAMP2 accelerates hepatic steatosis in HFD-induced NAFLD mice (Kim et al., 2015). However, we did not adopt liver specific deletion of STAMP2 for this study because the effect of cilostazol was evident after 9 weeks of cilostazol treatment while the effect of liver specific deletion mostly last for 2 weeks. Thus, to prove that cilostazol ameliorates lipid accumulation through STAMP2, further future research using STAMP2 knockout mice is required.

In conclusion, cilostazol increases hepatic STAMP2 expression and ameliorates hepatic steatosis not only in the liver of HFD-induced NAFLD mouse model but in HepG2 cells treated with OA. In addition, cilostazol improves HFD-induced hepatic steatosis by modulating hepatic STAMP2 expression through AMPK. Enhancing hepatic STAMP2 expression by cilostazol may be a potential therapeutic approach for the treatment of NAFLD.
Author contributions

Participated in research design: Oh, Kim, Yoo.


Performed data analysis: Kim, Yoo.

Wrote or contributed to the writing of the manuscript: Suh., Choi, Nam, S.Y. Lee, Yoo.
References


Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. *Gastroenterology* 123:134-140.


Jung YA, Kim HK, Bae KH, Seo HY, Kim HS, Jang BK, Jung GS, Lee IK, Kim MK and Park KG (2014) Cilostazol inhibits insulin-stimulated


MOL #113217


Footnotes

Conflicts of interest: The authors have no conflict of interest to declare.

Financial Support: This work was financially supported by the National Research Foundation of Korea (NRF) through a grant funded by the Korean Government (MISP) [2015R1A2A1A10051603].
Figure legends

Fig. 1. High throughput screening. (A) 1st screening (Singlet) (left). Confirmation screening (Triplicate) (right). To quantify the selectivity of compounds in the former class, as well as uncover compounds in the nonselective class that might display selectivity at lower doses, all 50 compounds were entered into a secondary screen using a drug concentration range. (B) Confirmation screening identified 13 upregulator compounds with 2-fold or greater selectivity.

Fig. 2. Cilostazol increases hepatic STAMP2 through transcriptional regulation in vivo and in vitro. (A) Immunohistochemical staining. (B) Real time PCR and (C) Western blot assay and quantification showing the effect of cilostazol treatment for 9 weeks on the expression of STAMP2 in the liver tissue obtained from C57BL/6 mice. n=9 per group. Veh, vehicle. n=9 per group. *p <0.05. (D) Luciferase assays showing the effects of 0~100 μM cilostazol (Cilo) on STAMP2 promoter activity in HepG2 cells. (E) Time sequenced luciferase assays showing the effects of 50 μM cilostazol on STAMP2 promoter activity in HepG2 cells. (F, G) The effect of cilostazol on the expression of STAMP2 mRNA and protein in HepG2 cells. (F) RT-PCR. (G) Western blot analysis.
**Fig. 3.** Cilostazol attenuates HFD-induced NAFLD in mice. (A) Experimental design. (B) Blood glucose and plasma insulin levels, and intraperitoneal glucose tolerance test (IPGTT). Assays were performed on SD- and HFD-fed mice with or without cilostazol for 9 weeks. n=9 per group. (C) Representative images of the livers obtained 9 weeks after treatment with cilostazol or vehicle. n=9 per group. Liver and body weights as well as the ratio of liver to body weight are illustrated (upper panel). Hematoxylin and eosin staining performed for the assessment of liver histology (below panel). (D) Measurement of plasma TC and plasma NEFA levels. n=9 per group. (E) Western blot analysis and quantification of the hepatic expression of LXRα and SREBP-1c. n=9 per group. *p <0.05.

**Fig. 4.** Cilostazol ameliorates lipid accumulation through hepatic STAMP2. (A) Immunohistochemical staining, and Western blot assay and quantification. The effect of cilostazol on the expression of STAMP2 in the liver tissue obtained from C57BL/6 mice. n=9 per group. (B) Oil Red O staining and Western blot analysis, and their quantification showing the effect of cilostazol treatment on the OA-induced lipid accumulation and lipogenic-related protein expression level in HepG2 cells. (C) Luciferase assay and Western blot analysis, and their quantification. The effect of cilostazol on the expression of STAMP2 in OA-induced HepG2 cells. (D) Western blot analysis and quantification showing the efficient depletion of STAMP2. (E)
Oil Red O staining and Western blot analysis, and their quantification showing the expression of LXRα and SREBP-1c in STAMP2-depleted cells. *p <0.05.

**Fig. 5.** AMPK involves in the amelioration of lipid accumulation by cilostazol. (A, B) Western blot analysis and quantification showing the effect of cilostazol on the expression of p-AMPKα. The liver of C57BL/6 mice, n=9 per group (A). HepG2 cells (B). (C, D) The effect of AICAR (AIC) or Compound C (CC) on the amelioration by cilostazol of lipid accumulation. Oli Red O staining and quantification (C), Western blot analysis and quantification of the expression of LXRα and SREBP-1c (D). *p <0.05.

**Fig. 6.** AMPK functions upstream of STAMP2. (A, B) The effect of AICAR or Compound C on the expression of STAMP2. (A) Relative luciferase assay. (B) Western blot analysis. (C) Relative luciferase assay showing that AICAR reversed oleic acid-induced down-regulation and that Compound C reversed cilostazol-induced up-regulation of STAMP2. (D) Western blot analysis and quantification showing that the ability of cilostazol to reverse the OA-induced decrease in STAMP2 expression was inhibited by Compound C but was augmented by AICAR. (E, F) Western blot analysis and quantification of the expression of p-AMPKα in STAMP2-depleted cells (siSTAMP2). The effect of AICAR or Compound C (E). The effect of cilostazol (F). (G) Oil Red O
staining and quantification showing the effect of AICAR in STAMP2-depleted cells. (H, I) Western blot analysis and quantification showing the effect of Ad-STAMP2 on the expression of p-AMPKα in AICAR or Compound C-treated (H) and cilostazol-treated (I) cells. (J) Oil Red O staining and quantification showing the effect of Ad-STAMP2 on Compound C-treated cells. *p <0.05.

**Fig. 7.** The underlying mechanism of the effect of cilostazol in HFD-induced NAFLD mice.
**Fig. 1.**

<table>
<thead>
<tr>
<th>Structure</th>
<th>785488</th>
<th>61470354</th>
<th>7939615</th>
<th>7737227</th>
<th>9007645</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st</td>
<td>2.24</td>
<td>2.62</td>
<td>2.71</td>
<td>4.66</td>
<td>2.26</td>
</tr>
<tr>
<td>2nd</td>
<td>2.13</td>
<td>2.60</td>
<td>2.38</td>
<td>4.95</td>
<td>2.09</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Structure</th>
<th>7002852</th>
<th>9076379</th>
<th>6552445</th>
<th>7973770</th>
<th>9910646</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st</td>
<td>2.23</td>
<td>2.06</td>
<td>2.44</td>
<td>2.34</td>
<td>2.29</td>
</tr>
<tr>
<td>2nd</td>
<td>2.04</td>
<td>2.18</td>
<td>2.18</td>
<td>2.27</td>
<td>2.21</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Structure</th>
<th>8051911</th>
<th>7999575</th>
<th>7976531</th>
</tr>
</thead>
<tbody>
<tr>
<td>1st</td>
<td>2.22</td>
<td>2.45</td>
<td>2.12</td>
</tr>
<tr>
<td>2nd</td>
<td>2.11</td>
<td>3.09</td>
<td>2.05</td>
</tr>
</tbody>
</table>
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.
Fig. 6.
Fig. 7.

Diagram showing the process of high fat diet leading to lipogenic factors SREBP-1c and LXRα, which induce hepatic steatosis. Cilostazol activates AMPK and STAMP2, leading to a decrease in lipogenic factors and improvement of hepatic steatosis.